Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin

Roulet, Alain, Puel, Olivier, Gesta, Stéphane, Lepage, Jean-François, Drag, Marlene, Soll, Mark, Alvinerie, Michel, Pineau, Thierry·2003·European Journal of Pharmacology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0014-2999(02)02955-2

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 25

  1. Campbell, 1993, Ivermectin, an antiparasitic agent, Med. Res. Rev., 13, 61, 10.1002/med.2610130103 · doi:10.1002/med.2610130103
  2. Campbell, 1984, Ivermectin: a review of efficacy and safety, J. Vet. Pharmacol. Ther., 7, 1, 10.1111/j.1365-2885.1984.tb00872.x · DOI · Paper page
  3. Conrad, 2001, Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1, Toxicology, 156, 81, 10.1016/S0300-483X(00)00354-1 · DOI
  4. De Silva, 1997, Anthelmintics. A comparative review of their clinical pharmacology, Drugs, 53, 769, 10.2165/00003495-199753050-00004 · DOI
  5. Didier, 1996, The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor, Anti-Cancer Drugs, 7, 745, 10.1097/00001813-199609000-00005 · DOI
  6. Eytan, 1999, Mechanism of action of P-glycoprotein in relation to passive membrane permeation, Int. Rev. Cyt., 190, 175, 10.1016/S0074-7696(08)62148-8 · DOI
  7. Fassler, 1991, Evaluation of the safety of ivermectin administered in a beef-based formulation to ivermectin-sensitive Collies, J. Am. Vet. Med. Assoc., 199, 457, 10.2460/javma.1991.199.04.457 · DOI
  8. Grobet, 1997, A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle, Nat. Genet., 17, 71, 10.1038/ng0997-71 · DOI · Paper page
  9. Lankas, 1997, P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity, Toxicol. Appl. Pharmacol., 143, 357, 10.1006/taap.1996.8086 · DOI · Paper page
  10. Leveille-Webster, 1995, The biology of the P-glycoproteins, J. Membr. Biol., 143, 89, 10.1007/BF00234655 · DOI
  11. Mealey, 2001, Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene, Pharmacogenetics, 11, 727, 10.1097/00008571-200111000-00012 · DOI · Paper page
  12. Nobmann, 2001, Ivermectin excretion by isolated functionally intact brain endothelial capillaries, Br. J. Pharmacol., 132, 722, 10.1038/sj.bjp.0703762 · doi:10.1038/sj.bjp.0703762
  13. Paul, 1987, Clinical observations in Collies given ivermectin orally, Am. J. Vet. Res., 48, 684
  14. Paul, 1991, Evaluating the safety of administration high doses of a chewable ivermectin tablet to Collies, Vet. Med., 86, 623
  15. Paul, 2000, Safety of moxidectin in avermectin-sensitive Collies, Am. J. Vet. Res., 61, 482, 10.2460/ajvr.2000.61.482 · DOI
  16. Pouliot, 1997, Reversal of P-glycoprotein-associated multidrug resistance by ivermectin, Biochem. Pharmacol., 53, 17, 10.1016/S0006-2952(96)00656-9 · DOI · Paper page
  17. Pulliam, 1985, Investing ivermectin toxicity in Collies, Vet. Med., 33
  18. Schinkel, 1994, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs, Cell, 77, 491, 10.1016/0092-8674(94)90212-7 · DOI · Paper page
  19. Schinkel, 1996, P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs, J. Clin. Invest., 97, 2517, 10.1172/JCI118699 · DOI · Paper page
  20. Sutherland, 1990, Development, pharmacokinetics and mode of action of ivermectin, Acta Leiden, 59, 161
  21. Tang-Wai, 1995, Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators, Biochemistry, 34, 32, 10.1021/bi00001a005 · doi:10.1021/bi00001a005
  22. Tranquilli, 1991, Assessment of toxicosis induced by high-dose administration of milbemycin oxime in Collies, Am. J. Vet. Res., 52, 1170, 10.2460/ajvr.1991.52.07.1170 · DOI
  23. Tsuji, 1998, P-glycoprotein-mediated efflux transport of anticancer drugs at the blood–brain barrier, Ther. Drug Monit., 20, 588, 10.1097/00007691-199810000-00024 · DOI
  24. Umbenhauer, 1997, Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism, Toxicol. Appl. Pharmacol., 146, 88, 10.1006/taap.1997.8225 · doi:10.1006/taap.1997.8225
  25. Yamazaki, 2001, In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results, J. Pharmacol. Exp. Ther., 296, 723

Cited by

See all 171

Metadata

Authors
Roulet, A., Puel, O., Gesta, S., Lepage, J.-F., Drag, M., Soll, M., Alvinerie, M., & Pineau, T.
Venue
European Journal of Pharmacology
Publisher
Elsevier BV
Published
2003-01
Volume
460
Issue
2-3
Pages
85-91
ISSN
0014-2999 (ISSN-L)
OpenAlex
W2066112168
Cited by
171
References
1
FWCI
3.88
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. https://app.cochat.ai/papers/10.1016/s0014-2999(02)02955-2
The paper
Roulet, A., Puel, O., Gesta, S., Lepage, J.-F., Drag, M., Soll, M., Alvinerie, M., & Pineau, T. (2003). MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. European Journal of Pharmacology. https://doi.org/10.1016/s0014-2999(02)02955-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.